Automate Your Wheel Strategy on BDTX
With Tiblio's Option Bot, you can configure your own wheel strategy including BDTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BDTX
- Rev/Share 1.2414
- Book/Share 2.3345
- PB 1.4585
- Debt/Equity 0.128
- CurrentRatio 8.7311
- ROIC 0.0299
- MktCap 193864697.0
- FreeCF/Share 0.3146
- PFCF 10.8468
- PE 13.3954
- Debt/Assets 0.102
- DivYield 0
- ROE 0.127
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | BDTX | Guggenheim | -- | Buy | -- | $8 | Sept. 4, 2025 |
| Resumed | BDTX | Raymond James | -- | Outperform | -- | $11 | July 1, 2025 |
News
BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?
Published: September 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Black Diamond shines with a 51.1% stock surge, fueled by silevertinib's progress and pipeline momentum in oncology.
Read More
Is the Recent Pipeline Progress on its NSCLC Drug Enough for BDTX?
Published: September 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Black Diamond focuses on silevertinib for NSCLC and GBM, with key trial readouts due in late 2025 and FDA feedback expected in 2026.
Read More
Black Diamond (BDTX) Upgraded to Strong Buy: Here's Why
Published: August 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Black Diamond (BDTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Are Medical Stocks Lagging Black Diamond Therapeutics (BDTX) This Year?
Published: August 18, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how Black Diamond (BDTX) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.
Read More
Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier
Published: March 25, 2025 by: Seeking Alpha
Sentiment: Positive
Black Diamond Therapeutics' strategic deal with Servier makes BDTX undervalued, with a $70M upfront payment and potential $710M in milestone payments and royalties. BDTX is trading below its net cash of $2.30 per share, presenting a major buying opportunity despite past shareholder losses. Aggressive selling by Biotech Growth N.V. caused recent price volatility, but this creates a buying opportunity given BDTX's strong fundamentals.
Read More
About Black Diamond Therapeutics, Inc. (BDTX)
- IPO Date 2020-01-31
- Website https://www.blackdiamondtherapeutics.com
- Industry Biotechnology
- CEO Mark A. Velleca
- Employees 24